Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rang in Aktien #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Aktienkurs
$0.25974701
Zuletzt synchronisiert: 2025-01-06
Marktkapitalisierung
$2.04M
Veränderung (1 Tag)
0.74%
Veränderung (1 Jahr)
0.00%
Land
FR
Handel Acticor Biotech SAS (ALACT)

Kategorie

Aktien-Split-Historie für Acticor Biotech SAS (ALACT)
Die Aktie Acticor Biotech SAS (Symbol: ALACT) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Sep 15, 2026 statt.
Eine ALACT-Aktie, die vor dem Sep 15, 2026 gekauft wurde, entspricht heute 0 ALACT-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH